Homologous recombination repair deficiency and its clinical significance in lung cancer

• HRD is present in about 25% of lung cancers, more common in adenocarcinoma and TP53-mutant tumors. • HRD-positive tumors show higher genomic instability, mutation burden, and immune infiltration. • HRD status predicts improved response to platinum chemotherapy and immune checkpoint inhibitors. • Assessment of HRD could guide personalized treatment strategies in lung cancer.